Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of salvianolic acid A as lipoprotein-associated phospholipase A2 inhibitor

A technology of salvianolic acid and lipoprotein, which is applied in the field of medicine and can solve problems such as unreported research

Inactive Publication Date: 2017-10-27
ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the study of salvianolic acid A as an inhibitor of lipoprotein-associated phospholipase A2 has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of salvianolic acid A as lipoprotein-associated phospholipase A2 inhibitor
  • New application of salvianolic acid A as lipoprotein-associated phospholipase A2 inhibitor
  • New application of salvianolic acid A as lipoprotein-associated phospholipase A2 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Effect of salvianolic acid A on Lp-PLA2 content in the serum of AS rats

[0023] Materials: salvianolic acid A, vitamin D3 injection, pentobarbital sodium, rat Lp-PLA2 ELISA detection kit, platelet activating factor acetylhydrolase analysis kit.

[0024] Experimental animals: SPF grade male SD rats, 6-8 weeks old, weighing 220-250 g.

[0025] (1) Experimental method

[0026] 1. Model establishment and group administration

[0027] 1.1 Model establishment

[0028] Male SD rats were adaptively fed for 1 week and used for model preparation. They were fed with high fat (1% cholesterol, 10% lard, 10% egg yolk powder, 0.5% No. 3 bile salt, 78.5% basal feed), and at the same time Inject 400,000 IU / kg of VD3. Two weeks after VD3 injection, aortic balloon injury was performed according to the literature. Rats were intraperitoneally anesthetized with 3% sodium pentobarbital (45 mg / kg), their necks were shaved, and their backs were fixed on a mouse board. The skin...

Embodiment 2

[0038] Example 2: Effect of salvianolic acid A on the expression of Lp-PLA2 mRNA in the aorta of AS rats

[0039] Materials: salvianolic acid A, vitamin D3 injection, pentobarbital sodium, reverse transcription kit, fluorescence quantitative kit, total RNA extraction kit.

[0040] Experimental animals: SPF grade male SD rats, 6-8 weeks old, weighing 220-250 g.

[0041] (1) Experimental method

[0042]1. Model establishment and group administration

[0043] 1.1 Model establishment

[0044] Male SD rats were adaptively fed for 1 week and used for model preparation. They were fed with high fat (1% cholesterol, 10% lard, 10% egg yolk powder, 0.5% No. 3 bile salt, 78.5% basal feed), and at the same time Inject 400,000 IU / kg of VD3. Two weeks after VD3 injection, aortic balloon injury was performed according to the literature. Rats were intraperitoneally anesthetized with 3% sodium pentobarbital (45 mg / kg), their necks were shaved, and their backs were fixed on a mouse board. ...

Embodiment 3

[0053] Example 3: The effect of salvianolic acid A on the expression of Lp-PLA2 protein in the aorta of AS rats.

[0054] Materials: salvianolic acid A, vitamin D3 injection, pentobarbital sodium, Lp-PLA2 antibody

[0055] Experimental animals: SPF grade male SD rats, 6-8 weeks old, weighing 220-250 g.

[0056] (1) Experimental method

[0057] 1. Model establishment and group administration

[0058] 1.1 Model establishment

[0059] Male SD rats were adaptively fed for 1 week and used for model preparation. They were fed with high fat (1% cholesterol, 10% lard, 10% egg yolk powder, 0.5% No. 3 bile salt, 78.5% basal feed), and at the same time Inject 400,000 IU / kg of VD3. Two weeks after VD3 injection, aortic balloon injury was performed according to the literature. Rats were intraperitoneally anesthetized with 3% sodium pentobarbital (45 mg / kg), their necks were shaved, and their backs were fixed on a mouse board. The skin of the neck was disinfected with iodine, and the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new application of salvianolic acid A as lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. High-fat feeding is combined with VD3 injection and a balloon injury technique to establish a rat atherosclerosis (AS) model, and the influence of the salvianolic acid A on the Lp-PLA2 content and activity of AS rat serum and the influence of the salvianolic acid A on the Lp-PLA2mRNA of an AS rat aorta can be researched. A result shows that the salvianolic acid A can be used for lowering the Lp-PLA2 content and activity of the AS rat serum, and carrying out down regulation on the expression of aorta Lp-PLA2 protein so as to perform an anti-AS function. Meanwhile, human pancreatic cancer BxPC3 nude mouse subcutaneous transplantation tumor model is established, the influence of the SAA (SalvianolicAcid A) of two administration routes on nude mice bearing the Lp-PLA2, cPLA2 and sPLA2 expression can be researched. A result shows that the contents of the Lp-PLA2, the cPLA2 and the sPLA2 in the serum and the tumor tissues and the peri-tumorous tissues of the nude mice bearing the tumor can be obviously lowered. The new application is opened up for the salvianolic acid A, and the salvianolic acid A can be expected to serve as the Lp-PLA2 inhibitor for various medical applications.

Description

technical field [0001] The invention belongs to the technical field of medicine, in particular to the new application of salvianolic acid A as an inhibitor of lipoprotein-associated phospholipase A2. Background technique [0002] Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a Ca 2+ Independent secretion of phospholipase A2, plasma Lp-PLA2 binds to lipoprotein particles, about 80% of which bind to low-density lipoprotein (LDL), especially small particle LDL, only 10% bind to high-density lipoprotein (HDL) combined. Lp-PLA2, secreted phospholipase A2 (sPLA2), and cytoplasmic phospholipase A2 (cPLA2) together constitute the phospholipase A2 (Phospholipase A2, PLA2) family. Studies have shown that cPLA2, sPLA2 and Lp-PLA2 play an important role in promoting inflammation and causing atherosclerosis (AS), and are closely related to the occurrence of cardiovascular events. Among them, Lp-PLA2, as a new inflammatory marker, is the focus of current research. Studies have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P9/10A61P9/00A61P3/10A61P35/00
CPCA61K31/216
Inventor 陈民利屠珏马全鑫杨钦钦戎亦骊陈小真
Owner ZHEJIANG CHINESE MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com